PHARMING GROUP Share Price Euronext Amsterdam
Stocks
NL0000377018
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - EUR | - |
|
| Market Cap | 867M 992M 797M 743M 1.41B 94.42B 1.43B 9.56B 3.72B 46.41B 3.72B 3.64B 160B | P/E 2026 * |
39.9x | P/E 2027 * | 33.9x |
|---|---|---|---|---|---|
| Enterprise Value | 835M 955M 767M 715M 1.36B 90.95B 1.38B 9.21B 3.58B 44.71B 3.59B 3.51B 154B | EV / Sales 2026 * |
2.07x | EV / Sales 2027 * | 1.75x |
| Free-Float |
98.51% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PHARMING GROUP
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 03/03/2025 | |
Kenneth Lynard
DFI | Director of Finance/CFO | 58 | 30/09/2025 |
Anurag Relan
CTO | Chief Tech/Sci/R&D Officer | 54 | 31/05/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Barbara Yanni
BRD | Director/Board Member | 71 | 10/12/2020 |
Mark Pykett
BRD | Director/Board Member | 62 | 10/12/2020 |
| Director/Board Member | 60 | 18/05/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.86% | +0.48% | +55.50% | +163.08% | 1,082B | |
| +3.57% | +3.29% | +68.60% | +61.03% | 633B | |
| +3.99% | +3.05% | +37.93% | +93.37% | 461B | |
| +3.86% | +1.64% | +32.57% | +24.89% | 339B | |
| -0.56% | +0.96% | +41.67% | +39.35% | 301B | |
| -0.08% | +1.30% | +32.15% | +44.48% | 292B | |
| -1.54% | +2.81% | -25.35% | -39.61% | 225B | |
| +3.55% | +4.41% | +25.45% | +66.28% | 202B | |
| +4.21% | +2.65% | +17.47% | +71.11% | 163B | |
| Average | +2.10% | +4.58% | +31.78% | +58.22% | 411.08B | |
| Weighted average by Cap. | +2.24% | +5.52% | +42.24% | +83.14% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 404M 462M 371M 346M 656M 43.95B 666M 4.45B 1.73B 21.6B 1.73B 1.7B 74.45B | 448M 512M 412M 384M 728M 48.77B 739M 4.94B 1.92B 23.97B 1.92B 1.88B 82.61B |
| Net income | 42.97M 49.16M 39.49M 36.81M 69.82M 4.68B 70.88M 474M 184M 2.3B 185M 181M 7.93B | 39.6M 45.29M 36.39M 33.92M 64.33M 4.31B 65.31M 437M 170M 2.12B 170M 166M 7.3B |
| Net Debt | -31.88M -36.47M -29.3M -27.31M -51.8M -3.47B -52.59M -352M -137M -1.71B -137M -134M -5.88B | -85.08M -97.32M -78.19M -72.88M -138M -9.27B -140M -939M -365M -4.55B -365M -357M -15.7B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
